InvestmentMay 22, 2026, 05:16 PM
ImmixBio Closes $140.65M Stock Offering
AI Summary
Immix Biopharma, Inc. announced the closing of its previously announced underwritten registered offering, raising approximately $140.65 million in net proceeds. The offering involved 16,778,524 shares of common stock at a price of $8.94 per share. This financing included leading U.S. biotechnology institutional investors and mutual funds, providing capital to support ImmixBio's position as a global leader in AL Amyloidosis and the development of its lead candidate NXC-201.
Key Highlights
- Immix Biopharma closed its underwritten registered offering of common stock.
- The offering generated approximately $140.65 million in net proceeds for ImmixBio.
- A total of 16,778,524 shares of common stock were offered.
- Shares were priced to the public at $8.94 per share.
- The financing included leading U.S. biotechnology institutional investors and mutual funds.
- Morgan Stanley served as the lead book-running manager for the offering.
Price Impact
More from IMMX